You are here

  • Home
  • Archive
  • Volume 60, Issue Suppl 1
  • OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)

Article metrics

Article menu
Download PDFPDF
Speaker abstracts 2001
Rheumatoid Arthritis – Treatment
OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)

 

Online download statistics by month:

Online download statistics by month: April 2016 to March 2024

AbstractFullPdf
Apr 20162115
May 2016812
Jun 20164012
Jul 20161405
Aug 2016402
Sep 20161908
Oct 2016101
Nov 2016602
Dec 2016302
Jan 20171706
Feb 2017801
Mar 201740010
Apr 20171101
May 2017803
Jun 20173906
Jul 2017154040
Aug 201794010
Sep 20173605
Oct 201772012
Nov 20174402
Dec 2017800
Jan 20183205
Feb 20188206
Mar 201862011
Apr 20187207
May 20183404
Jun 20182000
Jul 201822010
Aug 20182405
Sep 20181804
Oct 20181600
Nov 20181002
Dec 20181402
Jan 2019200
Feb 20191200
Mar 20193003
Apr 20192202
May 20192800
Jun 2019200
Jul 2019600
Aug 2019201
Sep 2019600
Nov 2019201
Dec 20191000
Jan 20201202
Feb 2020601
Mar 20203608
Apr 20201209
May 20201000
Jun 20201000
Jul 20201202
Aug 20201203
Sep 20202803
Oct 20201402
Nov 20202003
Dec 2020801
Jan 20211605
Feb 20211807
Mar 20211402
Apr 2021401
May 2021102
Jun 2021002
Jul 2021005
Aug 2021006
Sep 2021002
Oct 20218020
Nov 20212012
Dec 2021402
Jan 20223503
Feb 2022402
Mar 20221803
Apr 2022807
May 202212012
Jun 2022404
Jul 2022401
Aug 20221404
Sep 20221007
Oct 20221505
Nov 20221406
Dec 20221202
Jan 20232003
Feb 2023800
Mar 20232200
Apr 2023800
May 2023202
Jun 20231001
Jul 2023806
Aug 2023402
Sep 2023605
Oct 2023800
Nov 20231400
Dec 20231200
Jan 20242200
Feb 2024601
Mar 20245901
Total17452375